The HPV Epidemic and Cancer Burden

Satellite Conference and Live Webcast Friday, April 6, 2018 10:00 – 11:00 a.m. Central Time

Produced by the Alabama Department of Public Health Video Communications and Distance Learning Division

Faculty

Jennifer Young Pierce, MD, MPH
Professor of Interdisciplinary
Clinical Oncology
Senior Staff Physician,
Gynecologic Oncology
Leader, Cancer Control and Prevention
Mitchell Cancer Institute
University of South Alabama




Disclosures

No disclosures



Understanding the Burden HPV & CANCER



HPV Infection

- Most females and males will be infected with at least one type of mucosal HPV at some point in their lives
 - Estimated 79 million Americans currently infected
 - 14 million new infections/year in the US
 - HPV infection is most common in people in their teens and early 20s
- Most people will never know that they have been infected

Satterwhite et al. Sex Transm Dis. 2013

Latest Update: HPV Prevalence

- During 2011–2014, prevalence of any oral human papillomavirus (HPV) for adults aged 18–69 was 7.3%; highrisk HPV was 4.0%
- Any oral HPV was highest among non-Hispanic black adults
- Prevalence of any and high-risk oral HPV was higher in men than women


Latest Update: HPV Prevalence

- During 2013-2014, prevalence of any and high-risk genital HPV for adults aged 18-59 was 45.2% and 25.1% in men and 39.9% and 20.4% in women, respectively
- Prevalence of any and high-risk genital HPV was higher among non-Hispanic black than both non-Hispanic white and Hispanic men and women

McQuillan et al. NCHS Data Brief No. 280, April 2017

Cervical Cancer

- Cervical cancer is the most common HPVassociated cancer among women
 - 528,00 new cases and 266,000 deaths world-wide in 2012
 - 12,000 new cases and 4,000 deaths in the U.S. in 2013




Cervical Cancer

- Half of cervical cancers occur in women <50 years
 - A quarter of cervical cancers occur in women 25-39 years


https://nccd.cdc.gov/uscs/ and http://gco.iarc.fr/today/home


Cervical pre-cancer in U.S. females

- 1.4 million new cases of low grade cervical dysplasia
- 330,000 new cases of high grade cervical dysplasia



Koshiol Sex Transm Dis. 2004. Schiffman Arch Pathol Lab Med. 2003






number of girls under 13
years of age in the United
States


168,400:
number who will develop
cervical cancer if none
are vaccinated

number who will die from
cervical cancer if none are
vaccinated

Cancers Caused by HPV per Year, U.S., 2009-2013 Male Both Sexes Cervix 91% 10,600 10,600 75% 600 Vulva 69% 2,500 2,500 Penis 63% 700 700 1,600 4,800 Rectum 91% 70% 2,000 9,600 11,600 Oropharynx 19,400 12,100 31,500 TOTAL

HPV-associated Cancer Incid				
by Primary Site 0		roup, by Sex, 2012-2015 Female		
Primary Site Group	Rate	Count	Rate Ma	Count
Cervix	9.2	942	N/A	N/A
Vagina	0.6	75	N/A	N/A
Vulva	2.0	243	N/A	N/A
HPV-associated Oropharynx*	2.1	254	9.2	1,038
Anus	2.7	216	2.2	225
Rectum and Rectosigmoid Junction	0.4	52	0.2	24
Penis	N/A	N/A	0.9	89
Rates are per 100,000 and age-adjusted Rates and counts are for malignant turn		U.S. (19 age	groups) sta	ndard.
Includes the following ICIX-O-3 site co C100, C101, C102, C104, C108, C109, Ill cancer sites other than cervix were I ICD-O-3 histology codes 8050 to 8084 ource: Albhama Statewide Cancer Re-	des: C019, C0 C140, C142, 8 limited to squi and 8120 to 8	and C148. amous cell c		





Patient Videos

- Orophyrangeal cancer patient
- Someone you Love trailer

Cancer Diagnosis and Treatment

- Orophyrangeal cancers
 - Most diagnosed Stage II or greater
 - -Treated with life altering surgery or chemo/radiation or both
 - Survival is high 85-90% for lower stage disease

Cancer Diagnosis and Treatment

- Cervical cancer
 - -> 50% diagnosed late stage
 - Disparities in minorities
 - Treated with radical surgery or chemo/radiation
 - Most treatments result in loss of fertility
 - 1/3 will recur and die, including patients with Stage I

Economic Impact Related to HPV-Associated Disease, 2010

Event	Cost (\$ billions)
Cervical cancer screening*	6.6
Cervical cancer	0.4
Other anogenital cancers	0.2
Oropharyngeal cancer	0.3
Anogenital warts	0.3
RRP**	0.2
TOTAL	8.0

*Cervical cancer screening costs: ~ 80% routine screening, ~20% follow-up **RRP costs: ~ 70% juvenile-onset, ~ 30% adult-onset